Pulling SEC filings + quote and writing the call…

EyePoint, Inc.
Next earnings Aug 4, 2026 · consensus $-0.97 EPS, $416K rev
Last earnings -2.9% on 2026-05-06
Conservative balance sheet (liabilities/equity 0.19x); but revenue fell -27.5% YoY.
Revenue (FY2025) $31.4M · FY2025
EyePoint, Inc. shows $31.4M in FY2025 revenue (-27.5% YoY), a -739.4% net margin, and -75.8% ROE.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$55.3M | -$99.6M | -$75.1M | -$146M | -$243M |
| Net income | -$58.4M | -$102M | -$70.8M | -$131M | -$232M |
| Diluted EPS | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
| Net margin | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001314102, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:13:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 1 sale
| 2026-05-25 | Elston George Chief Financial Officer | Exercise | 7.50K | |
| 2026-05-25 | Elston George Chief Financial Officer | Tax | 3.63K @ $12.93 | $46.9K |
| 2026-04-17 | Ribeiro Ramiro Chief Medical Officer | Exercise | 2.44K @ $8.26 | $20.1K |
| 2026-04-17 | Ribeiro Ramiro Chief Medical Officer | Sell | 2.44K @ $15.00 | $36.6K |
| 2026-03-23 | Duker Jay S. President and CEO | Disposed (J) | 76.8K @ $13.11 | $1.01M |
| 2026-03-23 | Duker Jay S. President and CEO | Acquired (J) | 76.8K @ $13.11 | $1.01M |
| 2026-03-16 | Duker Jay S. President and CEO | Buy | 1.50K @ $13.15 | $19.7K |
| 2026-03-04 | Ribeiro Ramiro Chief Medical Officer | Exercise | 2.44K @ $8.26 | $20.1K |
| 2026-03-04 | Ribeiro Ramiro Chief Medical Officer | Sell | 2.44K @ $17.87 | $43.6K |
| 2026-03-02 | Elston George Chief Financial Officer | Gift | 5.00K | |
| 2026-03-02 | Elston George Chief Financial Officer | Gift | 5.00K | |
| 2026-02-17 | Ribeiro Ramiro Chief Medical Officer | Exercise | 2.44K @ $8.26 | $20.1K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1044 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.